Method of producing pyridazine amino-derivatives or their salts with acids

专利摘要:
A process for the preparation of pyridazine amino derivatives of the formula g RI- {-NH- € H2-av f o, N-N where R is 2-thienyl, 3-thienyl or daclohexyl; RZ is hydrogen or C-alkyl, or their salts with acids, characterized in that the chlorine derivative of the formula Ri4 -C1. N-N, where R and Rj have the indicated meanings, are reacted with an excess of the amine of formula S. NH2-CH2-CH - Qo. in the medium of alcohol at the boiling point of the reaction mixture and the target product is isolated in the free or in the form of a salt with an acid. from 00 4ik cl
公开号:SU1189345A3
申请号:SU843694357
申请日:1984-01-23
公开日:1985-10-30
发明作者:Кан Жан-Поль；Бизьер Катлеен；Вермут Камиль-Жорж
申请人:Санофи (Фирма)；
IPC主号:

专利说明:

The invention relates to a method for pucheni new chemical biologically active compounds, specifically to a method for obtaining new amino derivatives of pyridazine or their salts with acids that have an effect on the central nervous system.
The aim of the invention is to obtain new pyridazine amine derivatives having improved serotoninomimetic activity, cholinomimetic activity and a higher ability to inhibit monoamine oxidase activity.
Example 1. 3-Morpholinoethylamino-4-methyl-b- (2-thienyl) -pyrid ZIN dichlorgi; fat (CM 30387).
l) 7.-Hydroxy-2-meth B-3- (2-thenoyl) propanoic acid.
70.4 g of pyruvic acid are neutralized with 20% potassium hydroxide solution while stirring and cooling, then 101 g of 2-acetylthio (1) ene is added. A solution of 56 g of potassium hydroxide in 1600 is then added. ml of methanol. under stirring, then leave the mixture in the refrigerator for 4 days.
Acidify the solution with Yun. sulfuric acid to pH 3-4. Filter the precipitate of potassium sulfate and evaporate the methanol on a water bath in vacuo. The remaining solution is acidified with Yun. sulfuric acid and water is added to dissolve the potassium sulfate. Extraction is carried out with ether and the ether phase is washed twice with 100 ml of water. The organic solution is extracted with an aqueous solution of potassium bicarbonate. The aqueous phase is separated, which is extracted with a small amount of ether, then acidified with Yun. sulfuric acid.
The resulting acid is crystallized, dried and washed with a small amount of isopropyl ether. Used for the next step.
b) 4-Methyl-6- (2-tkenyl) -3-pyridazone.
20 g of the obtained acids are dissolved in 200 ml of butanol, then 7 g of hydrazine hydrate is added,
Heat the mixture at the boiling point of the reaction mixture, slowly distilling the azeotropic butanol-water azeotropic mixture. When water production ceases, distillation is distilled.
approximately 160 ml of butanol and left to crystallize under cooling.
Dehydrate the crystals and recrystallize from acetic acid. Get the target product: weight of 14.5 tons pl. .
c) 3-Chloro-4-methyl-6- (2-thiensh1) -pyridazine.
A mixture of 14 g of pyridazone obtained and 90 ml of phosphorus oxychloride is heated in a water bath for 3 hours. Pour the mixture onto layered ice and alkalinize with 20% sodium solution.
Dehydrate the solid and recrystallize from methanol. The weight of the obtained product 10.5 g, so pl. 146®С.
d) SM 30387 ..
A mixture of 10.0 g of chloropyridazine and 9 g of 2-morpholinostilamine in 150 mp of butanol is heated at the boiling point of the reaction mixture for 3 days.
Dissolve the solution in water and alkalinize with sodium solution. Extracted with ether, dissolved over sodium sulfate and concentrated to dryness in vacuo.
The residue crystallizes and is recrystallized from ethane acetate. Bes obtained product 9 g, T. pl. .
Dihydrochloride.
To a solution of 8.9 g of this base in 50 ml of isopropanol was added 3.5 ml of an aqueous solution of concentrated hydrochloric acid. The formed solid is dehydrated and recrystallized from absolute ethanol. The weight of the obtained product is 10.6 rj t. Pl. 234C. .
PR and m er 2, 3-Morpholinoethylamino-4-methylIl-6- (3-thiensh1) -pyridazine, dihydrochloride (CM 30388).
Analogously to example 1, but replacing 2-acetylthiophene with 3-acetylthiophene, 2-hydroxy-2-methyl-6- (3-thenoyl) propanoic acid is obtained successively; 4-methyl-6- (3-thienyl) -3-pyridazone, m.p. (acetic acid) i 3-chloro-4-methyl-6- (3-thienyl) -pyridazine, so pl. (dioxane); CM 30388; the base is mp. 56 ° C (ethyl acetate - petroleum
ether), dichlorohydrate - t. pl. 152 C (absolute alcohol).
Example 3. 3-Morpholinoethylamino-4-methyl-6-cyclohexn1 Pyridazine, dihydrochloride (CM 30390).
Analogously to Example 1, but replacing 2-acetylthiophene with cyclohexylmethylketone, 2-hydroxy-2-methyl-6-diclohexylpropanoic acid is obtained successively; 4-methyl-6-cyclohexyl-3-pyridazone, m.p. 173C (isopropanol-isopropyl ether) j 3-chl or-4-methyl-6-cyclo-ecylpyridazine is chromatographed on silica, elution is carried out with ethyl acetate-hexane (25J75 by volume)} CM 30390: base - yellow oil.
Calculated,%: C 54,10; H 8.01; N 14.85.
Found,%: C 53.99; H 7.97; N 14.83.
Dihydrochloride t. Pl. (isopropanol - ether).
The products obtained were subjected to pharmacological tests in order to determine their effect on the central nervous system.
1. Antidepressive activity.
Antagonism of ptosis caused by reserpine.
This experience is described by Gouret and is implemented: 3 in weight of a female CDI Charles Riker weighing 20 + 1 g. Reserpine causes ptosis 1 h after intravenous injection, some antidepressants counteract this ptosis.
The test substances were administered intraperitoneally. Reserpine was administered simultaneously intravenously at a dose of 2 mg / kg. One hour after administration of reserpine, the number of animals without ptosis was noted.
This experiment was carried out on batches for 10 smaller ones, the results were given in the percentage of animals that did not have ptosis, and represent an average of at least two experiments.
Potentiation of convulsions., Of head caused by 5-hydroxytryptophan.
5-Oxytriptophan, the precursor of 5-hydroxytryptamine, causes typical behavior in a mouse, characterized by sharp jerks of the ears (head cramps). Molecules that activate jDT central serotonergic
transmission, a number of head cramps, while tricyclic antidepressants are inert.
First, the test substance was administered intraperitoneally, then after 1 hour, one dose (200 mg / kg) of a suspension of 5-hydroxytroptophan in distilled water. Each animal (CDI Charles Riker's female CDI weighing 22-24 g) was immediately placed in a glass cylindrical glass. For 20 min, the number of head cramps was counted.
The effect of each dose of the test substance on a batch of 10 animals was compared to a control batch that received only excipient.
Vfazhapi results as a percentage of the ratio to the average obtained from control mice.
Measurement of monoamine oxidase (MAO) activity in vitro.
The inhibitory activity of monoaminoosidase was carried out according to the method described by Kap et al. When used as a source of the enzyme of the rat organism.
After dissection, tissues were homogenized in 16 vol. (weight per volume of ice-cold phosphate buffer solution (0.1 M, pH 7.40). Fractions O, 1 ml were incubated for 10 min in the presence of carbon-labeled 14-oxytryptamine 14 (final concentration 480 juM), and kitsichs concentrations of the test substance-, the final incubation volume was 0.5 MP.The acid metabolites were extracted in a 7 MP mixture of toluene and ethyl acetate 1: 1 (by volume), then counted as a result of liquid scintillation. inhibits 50% (ICyj) of the control activity.
2. Dopaminergic activity was investigated by analyzing the behavior of rotation in a mouse after unilateral damage to the body.
CDI Charles Riker female CDIs weighing 20–24 g were pre-applied one-sided damage by stereo-toxic injection of 6-oxidopamine at a rate of 8 μg per animal. One week after this operation, the test substances were injected intraperitoneally to groups of 7 mice.
One hour after the substance was injected, the rotation number was determined within 2 minutes. Independent lateral rotations for damage were considered positive, and lateral rotations from contact were considered negative.
The algebraic sum of the rotations of one; groups of treated animals were compared with the algebraic sum of rotations of the control animals group, which received only excipient (physiological solution of sodium chloride).
3. Cholinergic activity.
Cholinergic receptors such as muscarin can be labeled in vitro with pounded quinuclidinyl benzylate (QNB CH). This marking was performed according to the method described by Yahamura et al. .
The rat brain, from which the cerebellum was removed, was homogenized in 10 vol, (weight per volume) 0.32 M sucrose, then centrifuged at lOOOxg for 10 min. The precipitate was removed and the residue was homogenized again.
The multiple fractions of 0.1 ml were incubated for 1 hour in 2 ml of buffer phosphate (0.05 M, pH 7.4) containing varying concentrations of the test product and 0.05 nM QNB CH).
Then the samples were filtered on Whatman GF / B filters under a slight vacuum, washed with incubation buffer. Radioactivity, absorbed by filters, was counted as a result of liquid scintillation.
Non-specific fixation was determined in the presence of 100 M oxotremorine. ICj is graphically determined.
The results of the study of the effect of the proposed pyridazine amino derivatives on the central nervous system are presented in the table.
This table presents the results obtained in similar experiments with a known substance belonging to the chemical class of pyridazines, denoted by minaprine (DCI), corresponding to the formula
and being a close structural analogue of the proposed compounds of the aminopyridazine series.
The table shows that the proposed substances, when used as antidepressants, have better serotoninomimetic activity (experience with 5-HTP) and better inhibitory activity of monoamine oxidase than minaprin} they are more active as cholinomimetic agents (link to H-QNB) than minaprin) in addition, in contrast to minaprin, they are deprived of any popamine-mimetic activity. .
However, the proposed substances are of low toxicity, therefore, they can be used in medicine to treat depression and depressed states of any kind. These substances can be administered by mouth, rectum or by injection. The pharmaceutical compositions that contain them can be solid or limp and take the form of tablets, coated tablets, granules, suppositories or injections.
The dosage may vary at wide intervals depending on the method of administration and on the type and severity of the disease. In an adult, when administered orally, it is most often 0,010-0,500 g, if necessary, is distributed into several parts.
Example. Ralene drug.
Tablets in the shell, mg:
CM 30388. 100
Aerosil.
Stearate
magnesium 1.5
Starch
TA PX 1500 48

权利要求:
Claims (1)
[1]
A method of obtaining amino derivatives of pyridazine of the formula where R, is 2-thienyl, 3-thienyl or cyclohexyl;
R, is hydrogen or C,. -alkyl, or their salts with acids, characterized in that the chlorine derivative of the formula where R ₁ and R ₂ have the indicated meanings are reacted with an excess of the amine of the formula in alcohol at the boiling point of the reaction mixture and the target product is isolated in free or in the form of a salt with the sour one.

类似技术:

---

公开号 | 公开日 | 专利标题

---

EP0281459B1|1995-04-26|Dextrorotatory enantiomer of alpha-|methyl acetate, process for its preparation and pharmaceutical compositions containing it

---

US4110337A|1978-08-29|Triazolobenzodiazepines

---

US4721711A|1988-01-26|Pyridazine derivatives active on the central nervous system, and medicaments in which they are present

---

CN101233114A|2008-07-30|New imidazole carboxamides, useful to treat e.g. pathologies associated with the insulin resistance syndrome, are fructose-1,6-biphosphatase inhibitors

---

US4147780A|1979-04-03|α-Amino-phosphonous acids for inhibiting bacteria and yeast

---

FR2554719A1|1985-05-17|MEDICINES BASED ON NEW VINYL-6 FURO- | -PYRIDINE DERIVATIVES

---

WO2004016596A1|2004-02-26|Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders

---

DE69533194T2|2005-08-11|PYRAZOLO | CHINOXALINE AS PDGF RECEPTOR PROTEIN TYROSINE KINASE INHIBITORS

---

SU1189345A3|1985-10-30|Method of producing pyridazine amino-derivatives or their salts with acids

---

US4810705A|1989-03-07|Triazolo [3,4-b]pyridazines, process for their preparation and pharmaceutical compositions containing them

---

US5837706A|1998-11-17|Drug for neuroprotection

---

DE4444930A1|1996-06-27|2-amino-1,3-thiazepines and their use as inhibitors of nitric oxide synthase

---

US4044130A|1977-08-23|Compositions for the control of microorganisms

---

CA1203537A|1986-04-22|Process for the preparation of 2-piperazinopyrimidine derivatives

---

JPH09323928A|1997-12-16|Nerve differentiated induction agent

---

FR2610932A1|1988-08-19|NOVEL PIPERAZINECARBOXYLIC ACID, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT

---

Bambury et al.1984|Mesoionic pyridazine ribonucleosides. A novel biologically active nucleoside metabolite

---

US4576948A|1986-03-18|Composition and method for inhibiting terminal deoxyribonucleotidyl transferase activity

---

US4873243A|1989-10-10|Derivatives of 3-imino-pyridazine, process for obtaining them and pharmaceutical compositions containing them

---

EP0038731A2|1981-10-28|Thiazole derivatives, their preparation and use in therapeutics

---

US4317914A|1982-03-02|Oxazolines

---

US4016162A|1977-04-05|6-Morpholino-3-substituted phenyl-S-triazolo[4,3-b]pyridazines

---

BE897845A|1984-03-27|B-OXO-X-CARBAMOYL-PYRROLPTROPIONITRILES, PROCESS FOR THEIR PREPARATION PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AND THEIR APPLICATION

---

SU1427781A1|1992-04-23|4-aminocarbpnyl- or 4-aminoethyl-5-methylpyrazols displaying capability of controlling ethanol removal rate

---

JPH0665668B2|1994-08-24|Phenylpyrazine derivatives and antithrombotic agents

同族专利:

---

公开号 | 公开日

---

PT77982B|1986-04-10|

---

ES529007A0|1984-09-01|

---

EP0117171B1|1987-07-01|

---

US4524070A|1985-06-18|

---

IL70757A|1986-12-31|

---

ZA84501B|1984-09-26|

---

JPS59139367A|1984-08-10|

---

IE840150L|1984-07-24|

---

DK31584D0|1984-01-24|

---

FI840268A0|1984-01-23|

---

YU12384A|1986-10-31|

---

KR910000641B1|1991-01-31|

---

FI840268A|1984-07-25|

---

PT77982A|1984-02-01|

---

DE3464491D1|1987-08-06|

---

NO840244L|1984-07-25|

---

CS241539B2|1986-03-13|

---

DD238793A5|1986-09-03|

---

IL70757D0|1984-04-30|

---

EP0117171A1|1984-08-29|

---

KR840007409A|1984-12-07|

---

AU560542B2|1987-04-09|

---

CA1218063A|1987-02-17|

---

ES8407043A1|1984-09-01|

---

FR2539742B1|1986-09-05|

---

AT28077T|1987-07-15|

---

DK31584A|1984-07-25|

---

FR2539742A1|1984-07-27|

---

HU192390B|1987-06-29|

---

CS53084A2|1985-07-16|

---

NZ206907A|1987-03-31|

---

AU2372784A|1984-07-26|

---

GR81717B|1984-12-12|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB1292443A|1968-11-01|1972-10-11|Ct D Etudes Experimentales Et|New pyridazine derivatives and process for their preparation|

---

GB1345880A|1971-06-18|1974-02-06|Cepbepe|Pyridazine derivatives|WO1989001508A1|1987-08-19|1989-02-23|Martin Erich Klaus|Process for purifying and regenerating used oils|

---

US5631255A|1989-02-07|1997-05-20|Sanofi|Pyridazine derivatives|

---

US5461053A|1989-02-07|1995-10-24|Sanofi|Pyridazine derivatives|

---

PT93060B|1989-02-07|1995-12-29|Sanofi Sa|METHOD FOR OBTAINING PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

FR2665442B1|1990-07-31|1992-12-04|Sanofi Sa|ALKYL-6 PYRIDAZINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.|

---

JP5221952B2|2004-05-08|2013-06-26|ノバルティス・インターナショナル・ファーマシューティカル・リミテッド|3-Aryl-5,6-disubstituted pyridazines|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

FR8301029A|FR2539742B1|1983-01-24|1983-01-24|AMINO DERIVATIVES OF PYRIDAZINE SUBSTITUTED IN POSITION 6 BY A HETEROCYCLE OR ALICYCLE, SAID DERIVATIVES Being ACTIVE ON THE CENTRAL NERVOUS SYSTEM|

---